


Instructions for use
Tryptophan ELISA

REF

BA E-2700



IVD



Table of contents

1.	Introduction	3
1.1	Intended use and principle of the test	3
1.2	Clinical application	3
2.	Procedural cautions, guidelines, warnings and limitations	3
2.1	Procedural cautions, guidelines and warnings	3
2.2	Limitations	4
2.2.1	Interfering substances and proper handling of specimens	4
2.2.2	Drug and food interferences	4
2.2.3	High-Dose-Hook effect	4
3.	Storage and stability	4
4.	Materials	4
4.1	Contents of the kit	4
4.2	Calibration and Controls	6
4.3	Additional materials required but not provided in the kit	6
4.4	Additional equipment required but not provided in the kit	6
5.	Sample collection, handling and storage	7
6.	Test procedure	7
6.1	Preparation of reagents and further notes	7
6.2	Preparation of samples – Precipitation	7
6.3	Derivatization	8
6.4	Tryptophan ELISA	8
7.	Calculation of results	8
7.1	Expected reference value	9
7.2	Typical standard curve	9
8.	Control samples	9
9.	Assay characteristics	9
9.1	Performance data	9
9.2	Metrological Traceability	10
10.	References/Literature	10
11.	Changes	11

1. Introduction

1.1 Intended use and principle of the test

Enzyme immunoassay for the quantitative determination of L-tryptophan in urine, serum and EDTA-plasma samples for the determination of tryptophan homeostasis.

Tryptophan is present in the blood in protein-bound form. To isolate tryptophan, protein precipitation is first performed followed by a derivatization process. The subsequent competitive ELISA uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The analyte concentrations of the standards, controls and samples compete with the solid phase bound analyte concentrations for a fixed number of antibody binding sites. After the system is in equilibrium, free antigen and free antigen-antibody complexes are removed by washing. The antibody bound to the solid phase is detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate resulting in a colour reaction. The reaction is monitored at a wavelength of 450 nm.

Quantification of unknown samples is achieved by comparing their absorbance with a reference curve prepared with known standard concentrations. Manual processing of the ELISA is recommended. The use of automatic laboratory equipment is the responsibility of the user. This in-vitro diagnostic is for professional use only.

1.2 Clinical application

The amino acid L-tryptophan is essential for humans [1-4] and is absorbed through the diet [1, 2, 5, 6]. Tryptophan serves as a precursor in the synthesis of the neurotransmitters serotonin [2, 4-6] and tryptamine [2, 6] and the epiphyseal hormone melatonin [4, 7], among others. The enzyme indoleamine-2,3-dioxygenase (IDO) converts tryptophan to kynurenine [2, 5, 6]. Increased IDO activity is a sign of immunological dysregulation in humans, which is often described with infections [8] or even neurodegenerative diseases [8]. Furthermore, tryptophan and its metabolites regulate neurobehavioral patterns and may affect well-being (depressive symptoms) [9, 10].

Therapeutic consequences should never be based on laboratory results alone, even if these results are assessed in accordance with the quality criteria of the method. Any laboratory result is only a part of the total clinical picture of the patient.

Only in cases where the laboratory results are in an acceptable agreement with the overall clinical picture of the patient, it can be used for therapeutic consequences.

2. Procedural cautions, guidelines, warnings and limitations

2.1 Procedural cautions, guidelines and warnings

- (1) This kit is intended for professional use only. Users should have a thorough understanding of this protocol for the successful use of this kit. Only the test instruction provided with the kit is valid and must be used to run the assay. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- (2) This assay was validated for a certain type of sample as indicated in Intended Use (please refer to Chapter 1). Any off-label use of this kit is in the responsibility of the user and the manufacturer cannot be held liable.
- (3) The principles of Good Laboratory Practice (GLP) must be followed.
- (4) In order to reduce exposure to potentially harmful substances, wear lab coats, disposable protective gloves and protective glasses where necessary.
- (5) If serious incidents should occur in connection with this product, they should be reported to the manufacturer and the competent national authorities.
- (6) All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. For dilution or reconstitution purposes, use deionized, distilled, or ultra-pure water. Avoid repeated freezing and thawing of reagents and specimens.
- (7) The microplate contains snap-off strips. Unused wells must be stored at 2 – 8 °C in the sealed foil pouch with desiccant and used in the frame provided. Microtiter strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up.
- (8) Duplicate determination of sample is highly recommended.
- (9) Once the test has been started, all steps should be completed without interruption. Make sure that the required reagents, materials, and devices are prepared for use at the appropriate time.
- (10) Incubation times do influence the results. All wells should be handled in the same order and time intervals.
- (11) To avoid cross-contamination of reagents, use new disposable pipette tips for dispensing each reagent, sample, standard and control.
- (12) A standard curve must be established for each run.
- (13) The controls should be included in each run and fall within established confidence limits. The confidence limits are listed in the QC-Report provided with the kit.
- (14) Do not mix kit components with different lot numbers within a test and do not use reagents beyond expiry date as shown on the kit labels.
- (15) Avoid contact with Stop Solution containing 0.25 M H₂SO₄. It may cause skin irritation and burns. In case of contact with eyes or skin, rinse off immediately with water.
- (16) TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Rinse contaminated items before reuse.
- (17) For information about hazardous substances included in the kit please refer to Safety Data Sheet (SDS). The Safety Data Sheet for this product is made available directly on the website of the manufacturer or upon request.
- (18) Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.

- (19) The expected reference values reported in this test instruction are only indicative. It is recommended that each laboratory establishes its own reference intervals.
- (20) In case of any severe damage to the test kit or components, the manufacturer has to be informed in writing, at the latest, one week after receiving the kit. Severely damaged single components must not be used for a test run. They must be stored properly until the manufacturer decides what to do with them. If it is decided that they are no longer suitable for measurements, they must be disposed of in accordance with national regulations.
- (21) The results obtained with this test kit should not be taken as the sole reason for any therapeutic consequence but must be correlated to other diagnostic tests and clinical observations.

2.2 Limitations

Any inappropriate handling of samples or modification of this test might influence the results.

2.2.1 Interfering substances and proper handling of specimens

Serum/Plasma

Samples containing precipitates or fibrin strands might cause inaccurate results. Hemolytic samples (up to 2 mg/ml hemoglobin), icteric samples (up to 0.5 mg/ml bilirubin) and lipemic samples (up to 16 mg/ml triglycerides) have no influence on the assay results.

If the concentrations cannot be estimated and there are doubts as to whether the above limit values for hemolytic, icteric or lipemic samples are complied with, the samples should not be used in the assay.

2.2.2 Drug and food interferences

There are no known substances (drugs) which ingestion interferes with the measurement of tryptophan level in the sample. Fasting specimens or pre-feed specimens for children (2 – 3 hours after last meal) are advised.

2.2.3 High-Dose-Hook effect

No hook effect was observed in this test.




3. Storage and stability


Store kit and reagents at 2 – 8 °C until expiration date. Do not use kit and components beyond the expiry date indicated on the kit labels. Once opened, the reagents are stable for 2 months when stored at 2 – 8 °C (except reagent BA E-2428, see chapter 6.1). Once the resealable pouch of the ELISA plate has been opened, care should be taken to close it tightly again including the desiccant.

4. Materials

4.1 Contents of the kit

BA D-0024	REAC-PLATE	Reaction Plate – ready to use
Content:	1 x 96 well plate, empty, in a resealable pouch	
BA D-0090	FOILS	Adhesive Foil – ready to use
Content:	Adhesive foils in a resealable pouch	
Number:	1 x 4 foils	
BA E-0030	WASH-CONC 50x	Wash Buffer Concentrate – concentrated 50x
Content:	Buffer with a non-ionic detergent and physiological pH	
Volume:	1 x 20 ml/vial, purple cap	
BA E-0040	CONJUGATE	Enzyme Conjugate – ready to use
Content:	Goat anti-rabbit immunoglobulins conjugated with peroxidase	
Volume:	1 x 12 ml/vial, red cap	
Description:	Species is goat	
BA E-0055	SUBSTRATE	Substrate – ready to use
Content:	Chromogenic substrate containing 3,3',5,5'-tetramethylbenzidine, substrate buffer and hydrogen peroxide	
Volume:	1 x 12 ml/vial, black cap	
BA E-0080	STOP-SOLN	Stop Solution – ready to use
Content:	0.25 M sulfuric acid	
Volume:	1 x 12 ml/vial, grey cap	

BA E-2413	ASSAY-BUFF	Assay Buffer – ready to use
Content:	Buffer with alkaline pH	
Volume:	1 x 20 ml/vial, yellow cap	
Hazard pictograms:	 	
	GHS08 GHS07	
Signal word:	Danger	
Hazardous ingredients:	Boric acid	
Hazard statements:	H360FD May damage fertility. Suspected of damaging the unborn child.	
Precautionary statements:	P201 Obtain special instructions before use. P280 Wear protective gloves, protective clothing, eye protection, face protection. P308+P313 IF exposed or concerned: Get medical advice/attention. P501 Dispose of contents/container to an authorised waste collection point.	
Additional statements:	Restricted to professional users.	
BA E-2428	EQUA-REAG	Equalizing Reagent – lyophilized
Content:	Lyophilized protein	
Volume:	1 vial, brown cap	
Description:	Species is bovine	
BA E-2446	D-REAGENT	D-Reagent – ready to use
Content:	Crosslinking agent in dimethylsulfoxide	
Volume:	1 x 3 ml/vial, white cap	
Hazard pictograms:		
	GHS07	
Signal word:	Warning	
Hazardous ingredients:	Glutaraldehyde	
Hazard statements:	H317 May cause an allergic skin reaction.	
Precautionary statements:	P261 Avoid breathing mist/vapours/spray. P280 Wear protective gloves. P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P501 Dispose of contents/container to an authorised waste collection point.	
BA E-2458	Q-BUFFER	Q-Buffer – ready to use
Content:	TRIS buffer	
Volume:	1 x 20 ml/vial, white cap	
BA E-2710	AS TRYP	Tryptophan Antiserum – ready to use
Content:	Rabbit anti-L-tryptophan antibody in buffer with proteins and non-mercury preservative, blue coloured	
Volume:	1 x 6 ml/vial, blue cap	
Description:	Species of antibody is rabbit, species of protein in buffer is bovine	

BA E-2721	PREC-REAG	Precipitating Reagent – ready to use
Content:	Acidic reagent for precipitation of plasma/serum proteins, red coloured	
Volume:	1 x 4 ml/vial, white cap	
Hazard pictograms:		
	GHS05	
Signal word:	Danger	
Hazardous ingredients:	5-sulphosalicylic acid dihydrate	
Hazard statements:	H314 Causes severe skin burns and eye damage.	
Precautionary statements:	P280 Wear protective gloves, protective clothing, eye protection. P303+P361+P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310 Immediately call a doctor, a POISON CENTER. P501 Dispose of contents/container to an authorised waste collection point.	
BA E-2731	TRY	Tryptophan Microtiter Strips – ready to use
Content:	1 x 96 wells (12x8) antigen precoated microwell plate in a resealable blue pouch with desiccant	
BA E-2788	PBS	PBS – ready to use
Content:	Phosphate buffered saline	
Volume:	1 x 20 ml/vial, orange cap	

4.2 Calibration and Controls

Standards and Controls – ready to use

Cat. no.	Component	Colour/Cap	Concentration [µg/ml] TRY	Concentration [µmol/l] TRY	Volume/ Vial
BA E-2701	STANDARD A	white	0	0	4 ml
BA E-2702	STANDARD B	yellow	2.5	12.2	4 ml
BA E-2703	STANDARD C	orange	7.5	36.7	4 ml
BA E-2704	STANDARD D	blue	25	122	4 ml
BA E-2705	STANDARD E	grey	75	367	4 ml
BA E-2706	STANDARD F	black	250	1,224	4 ml
BA E-2751	CONTROL 1	green	Refer to QC-Report for expected value and acceptable range.		4 ml
BA E-2752	CONTROL 2	red			4 ml

Conversion: tryptophan [µg/ml] x 4.89 = tryptophan [µmol/l]

Content: Acidic buffer with non-mercury stabilizer, spiked with a defined quantity of tryptophan.

4.3 Additional materials required but not provided in the kit

- Water (deionized, distilled, or ultra-pure)
- Absorbent material (paper towel)
- Polystyrene or polypropylene tubes and suitable rack

4.4 Additional equipment required but not provided in the kit

- Calibrated precision pipettes to dispense volumes between 10 – 200 µl; 12.5 ml
- Microtiter plate washing device (manual, semi-automated or automated)
- ELISA reader capable of reading absorbance at 450 nm and if possible 620 – 650 nm
- Microtiter plate shaker (shaking amplitude 3 mm; approx. 600 rpm)
- Vortex mixer
- Centrifuge

5. Sample collection, handling and storage

Plasma

Whole blood should be collected by venepuncture into centrifuge tubes containing EDTA as anticoagulant (Monovette or Vacuette for plasma) and centrifuge according to manufacturer's instructions at room temperature immediately after collection.

Fasting specimens or pre-feed specimens for children (2 – 3 hours after last meal) are advised.

Hemolytic, icteric and lipemic samples should not be used for the assay.

Storage: up to 48 hours at 2 – 8 °C, for longer period (up to 6 months) at < -15 °C.

Serum

Whole blood should be collected by venepuncture into centrifuge tubes (Monovette or Vacuette for serum), allow to clot, and separate serum by centrifugation according to manufacturer's instructions at room temperature. Do not centrifuge before complete clotting has occurred. Samples of patients receiving anticoagulant therapy may require increased clotting time.

Fasting specimens or pre-feed specimens for children (2 – 3 hours after last meal) are advised.

Hemolytic, icteric and lipemic samples should not be used for the assay.

Storage: up to 48 hours at 2 – 8 °C, for longer period (up to 6 months) at < -15 °C.

Urine

Spontaneous urine (second morning urine) stabilized with 10 µl 6 M HCl per 1 ml of urine sample can be used. The measurement results are related to the creatinine content of the sample.

Storage: up to 48 hours at 2 – 8 °C; up to 6 months at < -15 °C.

Repeated freezing and thawing should be avoided. Avoid exposure to direct sunlight.

6. Test procedure

Allow all reagents and samples to reach room temperature and mix thoroughly by gentle inversion before use. Number the Reaction Plate and microwell plates (Microtiter Strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up). Duplicate determinations are recommended.

The binding of the antisera and of the enzyme conjugate and the activity of the enzyme are temperature dependent. The higher the temperature, the higher the absorption values will be. Varying incubation times will have similar influences on the absorbance. The optimal temperature during the enzyme immunoassay is between 20 – 25 °C.

If the product is prepared in parts, unused wells in Reaction Plates should be covered to avoid contamination. After preparation, the used wells must be labelled to prevent double use.

During the overnight incubation at 2 – 8 °C with the antiserum, the temperature should be uniform all over the ELISA plate to avoid any drift and edge-effect.

⚠ The use of a microtiter plate shaker with the following specifications is mandatory: shaking amplitude 3 mm; approx. 600 rpm. Shaking with differing settings might influence the results.

6.1 Preparation of reagents and further notes

Wash Buffer

Dilute the 20 ml Wash Buffer Concentrate **WASH-CONC** **50x** with water to a final volume of 1000 ml.

Storage: 2 months at 2 – 8 °C

Equalizing Reagent

Reconstitute the **EQUA-REAG** with 12.5 ml of **ASSAY-BUFF**. Reconstituted Equalizing Reagent which is not used immediately has to be stored in aliquots for max. 2 months at < -15 °C and may be thawed only once.

D-Reagent

The **D-REAGENT** has a freezing point of 18.5 °C. It must be ensured that the D-Reagent has reached room temperature and forms a homogenous, crystal-free solution.

Storage: 2 months at 2 – 8 °C

Tryptophan Microtiter Strips

In rare cases residues of the blocking and stabilizing reagent can be seen in the wells as small, white dots or lines. These residues do not influence the quality of the product.

6.2 Preparation of samples – Precipitation

1.	Pipette 20 µl of standards , controls and samples into the respective tubes.
2.	Add 200 µl PBS to all tubes.
3.	Add 25 µl PREC-REAG to all tubes.
4.	Mix the tubes thoroughly (vortex) and centrifuge for 15 min at 3,000 x g .
⚠	Take 25 µl of the clear supernatant for the derivatization .

6.3 Derivatization

1.	Pipette 25 µl of the precipitated standards, controls and samples into the respective wells of the REAC-PLATE .
2.	Add 50 µl of the Equalizing Reagent into all wells.
3.	Add 10 µl of the D-REAGENT into all wells.
4.	Cover plate with FOILS and incubate for 2 h at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
5.	Add 100 µl of the Q-BUFFER into all wells.
6.	Incubate for 10 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
⚠	Use 25 µl for the ELISA!

6.4 Tryptophan ELISA

1.	Pipette 25 µl of the derivatized standards, controls and samples into the appropriate wells of the W TRYP .
2.	Add 50 µl of the AS TRYP into all wells and mix shortly.
3.	Cover plate with FOILS and incubate for 15 – 20 h (overnight) at 2 – 8 °C .
4.	Remove the FOILS . Discard or aspirate the contents of the wells. Wash the plate 3 times by adding 300 µl of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
5.	Add 100 µl of the CONJUGATE into all wells.
6.	Incubate for 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
7.	Discard or aspirate the content of the wells. Wash the plate 3 times by adding 300 µl of Wash Buffer , discarding the content and blotting dry each time by tapping the inverted plate on absorbent material.
8.	Add 100 µl of the SUBSTRATE into all wells and incubate for 20 – 30 min at RT (20 – 25 °C) on a shaker (approx. 600 rpm).
⚠	Avoid exposure to direct sunlight!
9.	Add 100 µl of the STOP-SOLN to each well and shake the microtiter plate shortly.
10.	Read the absorbance of the solution in the wells within 10 min, using a microplate reader set to 450 nm (if available a reference wavelength between 620 nm and 650 nm is recommended).

7. Calculation of results

Measuring range	0.73 – 250 µg/ml
------------------------	------------------

The standard curve, which can be used to determine the concentration of the unknown samples, is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis) using a concentration of 0.001 µg/ml for Standard A (this alignment is mandatory because of the logarithmic presentation of the data). Use non-linear regression for curve fitting (e.g. 4-parameter, marquardt).

⚠ *This assay is a competitive assay. This means: the OD-values are decreasing with increasing concentrations of the analyte. OD-values found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.*

The concentrations of the samples and controls can be read directly from the standard curve.

Samples found with concentrations higher than the highest standard (Standard F) should be diluted accordingly with water (deionized, distilled, or ultra-pure) and must be re-assayed. For the calculation of the concentrations this dilution factor has to be taken into account.

Tryptophan related to the creatinine content of the sample: **mg/g creatinine** = $\frac{\text{mg tryptophan}}{\text{I}} : \frac{\text{g creatinine}}{\text{I}}$

Conversion:

tryptophan [µg/ml] x 4.89 = tryptophan [µmol/l]

7.1 Expected reference value

It is strongly recommended that each laboratory should determine its own reference values.


The expected reference values for serum and plasma samples indicated below are based on method comparison studies to LC-MS/MS [4]. The expected reference range for spontaneous urine was determined in an internal study by testing 62 samples (European population) (95% reference interval).

Expected reference value	Plasma/Serum	Spontaneous urine
	9.3 – 17.0 µg/ml 45.5 – 83.1 µmol/l	3.2 – 20.5 mg/g creatinine 15.6 – 101 µmol/g creatinine 1.8 – 11.4 mmol/mol creatinine

Values significantly outside the reference range should be assessed by a doctor.

7.2 Typical standard curve

⚠ Example: Do not use for calculation!



8. Control samples

It is recommended to use control samples according to national regulations. Use controls at both normal and pathological levels. Commercially obtained control samples should be treated like unknown samples. Control samples should fall within established confidence limits. The confidence limits of the kit controls are indicated on the QC-Report.

9. Assay characteristics

9.1 Performance data

Analytical Sensitivity	
Limit of Blank (LOB)	0.48 µg/ml
Limit of Detection (LOD)	0.65 µg/ml
Limit of Quantification (LOQ)	0.73 µg/ml

Analytical Specificity (Cross Reactivity)	
Substance	Cross Reactivity [%]
Tryptophan	100
5-Hydroxy-L-Tryptophan	< 0.01
5-Methoxy-L-Tryptophan	< 0.01
Tryptamine	< 0.01
5-Methoxytryptamine	< 0.01
5-Hydroxytryptamine	< 0.01

Precision					
Intra-Assay			Inter-Assay		
Sample	Mean ± SD [µg/ml]	CV [%]	Sample	Mean ± SD [µg/ml]	CV [%]
1	3.3 ± 0.9	26.7	1	2.8 ± 0.5	17.3
2	7.3 ± 1.1	14.7	2	7.7 ± 1.1	14.2
3	23.2 ± 2.2	9.3	3	23.4 ± 3.4	14.7
4	67.6 ± 4.4	6.4	4	66.4 ± 7.5	11.3

Lot-to-Lot			
	Sample	Mean ± SD [µg/ml]	CV [%]
Tryptophan in artificial matrix (n = 6)	1	6.5 ± 0.22	3.4
	2	31.5 ± 2.1	6.7
Tryptophan in plasma (n = 6)	1	10.1 ± 0.31	3.1
	2	48.5 ± 2.9	6.0

Recovery			
	Range [µg/ml]	Mean [%]	Range [%]
Urine	5.4 – 207	107	100 – 114
Serum	14.9 – 196	96	87 – 108
Plasma	12.1 – 202	100	89 – 110

Linearity		
Serial dilution up to	Mean [%]	Range [%]
1:64	94	73 – 115

Method Comparison: ELISA vs. LC-MS/MS	LC-MS/MS = 1.06x – 2.9; R ² = 0.99; n = 41
--	---

9.2 Metrological Traceability

The values assigned to the standards and controls of the Tryptophan ELISA are traceable to SI Units by weighing with quality-controlled analyte.

Standards and Controls	Uncertainty [%]
	2.1

Tryptophan ELISA	
Concentration [µg/ml]	Expanded Uncertainty [%] k = 2*
2.8	34.8
7.7	28.7
23.4	29.7
66.4	23.0

* This defines an interval about the measured result that will include the true value with a probability of 95%.

10. References/Literature

1. Metcalfe, A.J., et al., *Acute and chronic effects of exercise on the kynurenine pathway in humans - A brief review and future perspectives*. *Physiol Behav*, 2018. **194**: p. 583-587.
2. Platten, M., et al., *Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond*. *Nat Rev Drug Discov*, 2019. **18**(5): p. 379-401.
3. Roager, H.M. and T.R. Licht, *Microbial tryptophan catabolites in health and disease*. *Nat Commun*, 2018. **9**(1): p. 3294.
4. de Jong, W.H., et al., *Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry*. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2009. **877**(7): p. 603-9.
5. Addi, T., L. Dou, and S. Burtey, *Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease*. *Toxins (Basel)*, 2018. **10**(10).














6. Cervenka, I., L.Z. Agudelo, and J.L. Ruas, *Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health*. Science, 2017. **357**(6349).
7. Xu, K., G. Liu, and C. Fu, *The Tryptophan Pathway Targeting Antioxidant Capacity in the Placenta*. Oxid Med Cell Longev, 2018. **2018**: p. 1054797.
8. Strasser, B., et al., *Kynurenine pathway metabolism and immune activation: Peripheral measurements in psychiatric and co-morbid conditions*. Neuropharmacology, 2017. **112**(Pt B): p. 286-296.
9. Wigner, P., et al., *Oxidative and Nitrosative Stress as Well as the Tryptophan Catabolites Pathway in Depressive Disorders*. Psychiatr Danub, 2017. **29**(4): p. 394-400.
10. Wigner, P., et al., *The molecular aspects of oxidative & nitrosative stress and the tryptophan catabolites pathway (TRYCATs) as potential causes of depression*. Psychiatry Res, 2018. **262**: p. 566-574.

For updated literature or any other information please contact your local supplier.

11. Changes

Version	Release Date	Chapter	Change
15.0	2023-04-25	All	- The IFU was revised according to the IVDR regulation (EU) 2017/746
		1.	- Introduction updated
		2.1	- Procedural notes, guidelines and warnings updated
		2.2.2	- Drug and food interferences updated
		3.	- Shelf life extended after opening
		4.1	- BA E-2446 white cap (old: brown cap), Volume: 3 ml
		5.	- 24 h collection urine removed
		6.	- Stability of Wash Buffer and Equalizing Reagent adjusted
		7.	- Calculation of results specified
		9.1	- Lot-to-Lot added
		9.2	- Metrological traceability added
		10.	- References/Literature updated
		11.	- Chapter Changes added
16.0	2024-02-21	4.1	- Hazard labelling updated according to SDS
17.0	2024-09-26	7	- Note added to the dilution factor in the calculation
		9.2	- Metrological traceability updated

Symbols:

	Storage temperature		Manufacturer		Contains sufficient for <n> tests
	Use-by date		Batch code		For in-vitro diagnostic use only!
	Consult instructions for use		Content		CE marking of conformity
	Caution		Catalogue number		Distributor
	Date of manufacture				